沙美特罗/氟替卡松联合噻托溴铵治疗D组稳定期COPD患者的临床研究  

The clinical research of salmeterol/fluticasone combined tiotropium in treatment of group D stable COPD patients

作　　者：江宏志[1] 张平[1] 黄潘文[1] 

机构地区：[1]广东省东莞市人民医院呼吸内科,广东东莞523000

出　　处：《中国现代医生》2016年第18期38-40,共3页China Modern Doctor

基　　金：广东省东莞市科技计划项目(B200935)

摘　　要：目的探讨沙美特罗/氟替卡松与噻托溴铵联合治疗D组稳定期慢性阻塞性肺疾病(COPD)患者的效果。方法将90例D组稳定期COPD患者分为三组:A组(沙美特罗/氟替卡松+噻托溴铵)、B组(沙美特罗/氟替卡松)和C组(噻托溴铵),每组各30例。对三组患者治疗前和治疗3个月后的呼吸困难评分、肺功能指标进行比较。结果治疗3个月后,A组患者呼吸困难评分及肺功能改善均优于B、C两组,差异有统计学意义(P<0.05)。结论联合使用沙美特罗/氟替卡松和噻托溴铵比单用沙美特罗/氟替卡松或单用噻托溴铵可以更好地改善D组稳定期COPD患者的呼吸困难评分和肺功能。Objective To explore the therapy efficacy of salmeterol/fluticasone combined tiotropium in treatment of group D stable COPD patients. Methods 90 cases of group D stable COPD patients were randomly divided into three groups, group A（salmeterol/fluticasone combined tiotropium）, group B（salmeterol/fluticasone） and group C（tiotropium）, 30 patients in each group. The dyspnea score and lung function were measured before and 3 months after the treatment respectively. Results Compared with the other groups, the dyspnea score and lung function were significantly improved in group A after 3 months treatment,the difference was statistically significant （P〈0.05）. Conclusion Combination treatment with salmeterol/fluticasone and tiotropium results in greater therapeutic benefits than salmeterol/fluticasone or tiotropium alone in group D stable COPD patients.

关 键 词：慢性阻塞性肺疾病 沙美特罗/氟替卡松 噻托溴铵 呼吸困难评分 肺功能 

分 类 号：R563.9[医药卫生—呼吸系统]